- Satellos Bioscience’s (MSCL) co-founder and Chief Scientific Officer Dr. Michael Rudnicki received a prestigious grant award from Defeat Duchenne Canada
- The award is the country’s only national charity dedicated to ending Duchenne muscular dystrophy (“Duchenne”)
- The grant, awarded to the OHRI where Dr. Rudnicki is based, is for his discovery of a protein called Wnt7a and its role in stem cell division and potentially, as a treatment for Duchenne
- Satellos is a biotechnology company which focuses on developing lifechanging medicines to treat degenerative muscle conditions
- Satellos Bioscience Inc. (MSCL) remains steady, trading at C$0.42 per share as of 12:45 pm ET
Satellos Bioscience’s (MSCL) co-founder and Chief Scientific Officer, Dr. Michael Rudnicki, received a prestigious grant award from Defeat Duchenne Canada.
Dr. Rudnicki was one of only three 2022 recipients. The award is the country’s only national charity dedicated to ending Duchenne muscular dystrophy (“Duchenne”).
Frank Gleeson, the Co-Founder and CEO of Satellos commented on the news.
“We’re very excited for Michael and his academic team at the Ottawa Hospital Research Institute (“OHRI”). They continue to develop game changing science that can greatly improve the quality of treatment and life for those with Duchenne and other muscular dystrophies. This type of grant funding is key in supporting Canada’s research ecosytem by enabling translational research and advancement of new discoveries with potential to help patients.”
The grant awarded to the OHRI, where Dr. Rudnicki is based, is for his discovery of a protein called Wnt7a and its role in stem cell division and, potentially, as a treatment for Duchenne. Satellos has exclusively licensed rights to a portfolio of granted patents and patent applications related to Wnt7a from the OHRI. The Company believes Wnt7a has therapeutic potential.
Defeat Duchenne Canada, previously known as Jesse’s Journey, has provided more than $16M in funding over its 27-year history. This includes financial support in prior years to both Satellos and Dr. Rudnicki.
“This new grant to further our work on the systemic delivery of Wnt7a as a potential protein therapeutic has the potential to create proof of concept and underpin a future second development program in Satellos, a key aim. I would like to thank Defeat Duchenne Canada for this grant and their ongoing leadership in driving innovation in science,” says Dr. Michael Rudnicki, Co-founder and Chief Scientific Officer of Satellos Bioscience Inc.
“We are proud to support Dr. Rudnicki. His original insights into regeneration have the potential to change our fundamental understanding of Duchenne,” siad Perry Esler, CEO of Defeat Duchenne Canada.
Satellos is a biotechnology company that develops life-changing medicines to treat degenerative muscle conditions. Its lead program focuses on creating an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation. Satellos identifies this as a root cause of the progressive nature of this disease.
Satellos Bioscience Inc. (MSCL) remains steady, trading at C$0.42 per share as of 12:45 pm ET.
